OREANDA-NEWS. Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®), will be shared during an oral presentation at the American Thoracic Society (ATS) Conference in Denver, Colorado, USA.

The oral presentation covering results from key subgroup populations will be given by Dr. Kelly Chin of the University of Texas Southwestern Medical Center, Dallas, Texas, US at 15.45 on May 17, 2015. 

The ATS Conference will also see the presentation of further information from the macitentan (Opsumit®) Phase III SERAPHIN study in a poster discussion session with a poster titled 'Prognostic Indicators of Long-Term Outcome in Pulmonary Arterial Hypertension: Results from the SERAPHIN Event-Driven Morbidity/Mortality Trial' to be presented by Dr. Marion Delcroix of the University of Leuven, Leuven, Belgium from 09.30-11.30 on May 20, 2015. 

Additional pre-clinical data on macitentan will be presented in a poster titled 'Therapeutic Effect of Macitentan, a Novel Dual Endothelin Receptor Antagonist, on Right Ventricular Structure and Function in Pulmonary Arterial Hypertensive Rats' from 11.30-13.15 on May 17, 2015. 

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.